Pipeline
UC-MSC
Umbilical cord-derived mesenchymal stem cells (UC-MSCs) have emerged as a promising therapeutic platform due to their regenerative, immunomodulatory, and anti-inflammatory properties. These cells have shown significant potential in treating various degenerative and inflammatory diseases by promoting tissue repair and modulating immune responses. Our UC-MSC-based therapies are being developed to address unmet medical needs in cardiovascular and neurodegenerative disorders.
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-UC001
Heart failure
JY-UC002
Parkinson's disease
JY-UC003
ALS
JY-UC001 (Heart Failure)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-UC001
Heart failure
Heart failure (HF) associated with stable coronary artery disease (CAD) is a condition characterized by the progressive weakening of cardiac function due to chronic ischemia and impaired myocardial perfusion. Despite current pharmacological and interventional treatments, many patients continue to experience declining heart function and poor quality of life. JY-UC001 is our allogeneic UC-MSC therapy designed for the treatment of heart failure in patients with stable coronary artery disease. By leveraging the regenerative and paracrine effects of UC-MSCs, this therapy aims to enhance myocardial repair, reduce inflammation, and improve cardiac function, potentially offering a novel therapeutic approach for patients who have limited options beyond conventional treatment. We are advancing JY-UC001 through preclinical and early clinical development, evaluating its safety, efficacy, and long-term benefits in improving cardiac function and patient outcomes.
JY-UC002 (Parkinson's Disease)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-UC002
Parkinson's disease
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor impairments, cognitive decline, and significant disability. Current treatments focus primarily on symptom management, with no available cure to halt or reverse disease progression. JY-UC002 is our allogeneic UC-MSC therapy designed for the treatment of Parkinson’s disease. By leveraging the neuroprotective, anti-inflammatory, and trophic factor-secreting properties of UC-MSCs, this therapy aims to slow disease progression, promote neuronal survival, and improve functional outcomes in patients with PD. The development of JY-UC002 is focused on validating its therapeutic potential through rigorous clinical studies, with the aim of establishing a regenerative medicine approach for Parkinson’s disease patients.
JY-UC003 (ALS)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-UC003
ALS
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the degeneration of motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ultimately respiratory failure. Current treatments primarily focus on symptom management and modestly slowing disease progression, but there is no cure to halt or reverse neuronal loss. JY-UC003 is our allogeneic UC-MSC therapy designed for the treatment of ALS. By leveraging the neuroprotective, anti-inflammatory, and trophic factor-secreting properties of UC-MSCs, this therapy aims to slow motor neuron degeneration, reduce inflammation, and improve functional outcomes in ALS patients. The development of JY-UC003 is focused on validating its therapeutic potential through rigorous clinical studies, with the goal of establishing a regenerative medicine approach for ALS treatment.